We experienced a case of COVID-19 with hypoxia, which was presumed to be due to the development of ventilation and blood flow imbalance by pulmonary intravascular coagulopathy or hypoxic pulmonary vasoconstriction. Early, short-term combination therapy with remdesivir, nafamostat mesilate and low-dose dexamethasone was extremely effective.